U.S. District Court Upholds Validity of Lilly's Alimta Patent Through 2022
"We are pleased with the District Court's ruling on Alimta's vitamin dosage regimen patent and are confident that the patent is valid and enforceable," said
About
Lilly is a global healthcare leader that unites caring with discovery to make life better for people around the world. We were founded more than a century ago by a man committed to creating high-quality medicines that meet real needs, and today we remain true to that mission in all our work. Across the globe, Lilly employees work to discover and bring life-changing medicines to those who need them, improve the understanding and management of disease, and give back to communities through philanthropy and volunteerism. To learn more about Lilly, please visit us at www.lilly.com and http://newsroom.lilly.com/social-channels. C-LLY
This release contains forward-looking statements regarding the U.S. Alimta patent litigation. These statements are based on management's current expectations but actual results may differ materially. There can be no assurance that the company will prevail in any appeal. Also, the company cannot predict whether generic pemetrexed will be marketed prior to the resolution of this litigation. Other risk factors that may affect the company's results can be found in the company's latest Forms 10-K and 10-Q filed with the
Alimta® (pemetrexed, Lilly)
Refer to: (317) 433-9899 (office); (317) 985-6303 (cell) -
Logo- http://photos.prnewswire.com/prnh/20031219/LLYLOGO
SOURCE
News Provided by Acquire Media